I-Mab is a biopharmaceutical company that is dedicated to discovering and developing innovative biologics to address unmet medical needs. Their corporate philosophy revolves around a patient-centric approach, focusing on improving patients' lives through advanced therapies. I-Mab values integrity, collaboration, and scientific excellence, aiming to provide breakthrough treatments for diseases with high unmet medical needs. With a strong commitment to delivering novel solutions, I-Mab continuously strives to be at the forefront of research and development in the biopharmaceutical industry.

I-Mab is primarily present in China and the United States.

I-Mab, a leading biopharmaceutical company, has achieved significant milestones throughout its journey. The company successfully conducted a Phase 3 clinical trial for its innovative therapy in treating diffuse large B-cell lymphoma, demonstrating its commitment to advancing healthcare solutions. Additionally, I-Mab received the U.S. FDA Fast Track Designation for its potential treatment of multiple myeloma, recognizing the company's dedication to developing breakthrough therapies. Furthermore, I-Mab forged strategic partnerships with renowned global pharmaceutical companies, reinforcing its position in the global market. Overall, I-Mab's achievements highlight its exceptional growth and commitment towards improving patients' lives through groundbreaking treatments.

I-Mab is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2016, I-Mab focuses on the discovery and development of antibody-based drugs by leveraging its proprietary discovery and development platforms. This Chinese company has a strong emphasis on research and development, working on a diverse pipeline of potential drugs targeting various diseases. With a commitment to delivering novel and effective solutions, I-Mab has garnered recognition within the pharmaceutical industry for its innovative approach and dedication to improving patients' lives.

The main competitors of I-Mab in the market include large biopharmaceutical companies such as Junshi Biosciences, Legend Biotech, BeiGene, and Innovent Biologics.

I-Mab is primarily active in the pharmaceutical industry.

I-Mab is a clinical-stage biopharmaceutical company based in China. Its business model revolves around the discovery, development, and commercialization of innovative and differentiated biologics. I-Mab focuses on developing novel antibodies to address unmet medical needs in the fields of oncology, immuno-oncology, and autoimmune diseases. With a strong pipeline of potential therapies, I-Mab aims to bring groundbreaking treatments to patients globally. By advancing its drug candidates through rigorous research and strategic partnerships, I-Mab aims to revolutionize healthcare and improve patient outcomes.

I-Mab KGV ir -4,35.

I-Mab KUV ir 2605,55.

AlleAktien kvalitātes vērtējums I-Mab ir 1/10.

gaidāmā I-Mab apgrozījums ir 765 000,00 CNY.

gaidāmā I-Mab peļņa ir -458,28 milj. CNY.

I-Mab is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious diseases like cancer and immune disorders. They have a strong pipeline of products in the fields of oncology, autoimmune diseases, and cardiovascular diseases. They have partnerships with other companies to market their products worldwide. Overall, their business model is centered around developing and marketing effective therapies for challenging diseases and they have a unique partnership strategy.

I-Mab izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt I-Mab vai uzņēmums nedod dividendes.

I-Mab ISIN ir US44975P1030.

I-Mab WKN ir A2PVC6.

I-Mab simbols ir IMAB.

Pēdējo 12 mēnešu laikā I-Mab maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos I-Mab plāno maksāt dividendes 0 CNY apmērā.

I-Mab pašreizējā dividendu rentabilitāte ir .

I-Mab maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

I-Mab pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

I-Mab tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu I-Mab apmērā 0 CNY, kas tika izmaksāta 31.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 31.07.2024..

Pēdējās dividendes izmaksa notika 31.07.2024..

Gadā 2023, I-Mab izmaksāja 0 CNY dividendes.

I-Mab dividendes tiek izmaksātas CNY.